Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Dr Najib Rahman from the Oxford University Hospitals NHS Trust talks about the SIMPLE trial, funded by Marie Curie

Clinical Trials

ATOM: Atovaquone tumour hypoxia modifieR

Cancer cells often have lower oxygen levels than normal cells, which is called hypoxia. This lower level of oxygen can make the cancer cells resistant to traditional chemotherapy treatments. Drugs that can raise the oxygen levels in cancer cells may improve how well cancer treatment works.

This pre-operative window of opportunity study will use functional imaging and blood tests to see whether the drug atovaquone can increase tumour oxygen levels in patients with non-small cell lung cancer.

This trial is run by OCTO.

Vicky Strauss

Palliative Thoracic Radiotherapy Plus BKM120

Non-small cell lung cancer is usually treated with radiotherapy. Adding a drug that blocks cancer cell growth might make the tumours more sensitive to the radiotherapy. One candidate drug is BKM120.

This phase I CRUK trial tests whether BKM120 is safe to give to lung cancer patients having radiotherapy treatment and whether it works well. It will identify the best dose of BKM120 to give with lung radiotherapy.

Sharon Love and Pradeep Virdee

RESPECT-MESO: IMPACT OF REGULAR EARLY SPECIALIST SYMPTOM CONTROL TREATMENT ON QUALITY OF LIFE IN MALIGNANT MESOTHELIOMA

RESPECT-Meso logoRESPECT-Meso is a multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist palliative care treatment on quality of life in malignant mesothelioma. It will determine whether early specialist palliative care involvement improves mesothelioma patients’ and carers’ quality of life .

Susan Dutton and Stephen Gerry

SIMPLE: SONOGRAPHIC AND BIOLOGICAL INDICATORS OF MALIGNANT PLEURAL EFFUSION EFFICACY

SIMPLE logoCancer can cause fluid to build up between the layers of tissue that surround the lungs. The resulting pleural effusion causes breathlessness. This is a randomised trial to find sonagraphic or biological indicators of the extent of malignant pleural effusion. Indicators can be used in diagnosis and to track how well a treatment is working.

SIMPLE is run by the Respiratory Trials Unit, with the Oxford Pleural Unit, and funded by Marie Curie. Dr Najib Rahman from the Oxford University Hospitals NHS Trust talks about the trial in the video at the top of the page.

Susan Dutton and Lei Clifton